Business Responsibility and Sustainability Report for the Financial Year 2025-26

Emcure Ref: EPL/CS/SE/0076/2026 Date: August 28, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai - 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Business Responsibility and Sustainability Report for the Financial Year 2025-26 Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Business Responsibility and Sustainability Report for the Financial Year 2025-26. The said Report forms an integral part of the Annual Report of the Company for Financial Year 2025-26. The same is also being uploaded on the website of the Company i.e. www.emcure.com. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Pharmaceuticals Limited Business Responsibility and Sustainability Report DIRECTOR’S MESSAGE Dear Stakeholders, It gives me immense pleasure to present Emcure Pharmaceuticals Limited’s Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. This report reflects our continued commitment towards responsible business practices, sustainable growth, ethical governance, and creating long-term value for all our stakeholders. At Emcure, our purpose is driven by the belief of making quality healthcare accessible to patients across the globe. Over the years, we have built a strong presence across diverse therapeutic segments through our focus on innovation, research excellence, operational efficiency, and patient-centric solutions. Our commitment extends beyond business performance to creating a positive impact on society and the environment. Sustainability remains an integral part of our business strategy. We continuously strive to strengthen our environmental stewardship by improving resource efficiency, reducing emissions, optimising energy consumption, promoting responsible waste management, and enhancing water conservation practices across our operations. We remain committed to identifying and managing climate-related risks and opportunities while supporting a more sustainable future. Our people continue to be our greatest strength. We are focused on fostering a safe, diverse, equitable, and inclusive workplace that encourages collaboration, innovation, continuous learning, and professional growth. Through employee engagement initiatives, capability-building programs, and a strong culture of respect and integrity, we aim to create an environment where every individual can thrive and contribute meaningfully to organisational success. As a responsible corporate citizen, we actively contribute towards community development through initiatives focused on healthcare access, education, environmental sustainability, skill development, and social well-being. Through our CSR programs, we seek to create a lasting positive impact and contribute to inclusive and equitable growth. We continue to strengthen our governance framework through transparency, accountability, ethical conduct, and robust risk management practices. Our focus on data privacy, cybersecurity, regulatory compliance, and responsible business conduct enables us to maintain stakeholder trust and build long-term resilience. As we move forward, we remain committed to integrating sustainability principles across our value chain and business operations. We believe that responsible growth, innovation, and stakeholder collaboration will continue to drive our success while creating sustainable value for patients, employees, communities, investors, and society at large. I would like to express my sincere gratitude to our employees, customers, healthcare professionals, business partners, shareholders, and all stakeholders for their continued trust and support in our journey. Together, we will continue to advance healthcare solutions while building a more sustainable and responsible future. Regards, Sunil Mehta Whole-time Director Emcure Pharmaceuticals Limited 134 Annual Report 2025-26 Statutory Reports Annexure II BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORTING FORMAT SECTION A: GENERAL DISCLOSURES I. Details of the listed entity Corporate Identity Number (CIN) of the Listed Entity L24231PN1981PLC024251 Name of the Listed Entity Emcure Pharmaceuticals Limited Year of Incorporation 1981 Registered Office Address Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune – 411057, Maharashtra, India Corporate Address Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune – 411057, Maharashtra, India E-mail investors@emcure.com Telephone +91 20 3507 0033 and +91 20 3507 0000 Website https://www.emcure.com/ Financial Year for which reporting is being done 01 April 2025, to 31 March 2026 Name of the Stock Exchange(s) where shares are listed National Stock Exchange of India Limited and BSE Limited Paid-up Capital INR 1,895,895,470/- Name and contact details (telephone, email address) of Ms. Amruta Yangalwar the person who may be contacted in case of any queries Company Secretary and Compliance Officer on the BRSR report investors@emcure.com +91 20 3507 0033 and +91 20 3507 0000 Reporting Boundary- Are the disclosures under this report Standalone made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together) Name of Assurance Provider TÜV Rheinland India Pvt Ltd Type of Assurance Obtained Reasonable level of Assurance for the BRSR core indicators and Limited Level of Assurance- BRSR Disclosures II. Products/services 16. Details of business activities (accounting for 90% of the turnover): Description of Main Activity Description of Business Activity % of Turnover of the entity 1 Manufacturing Manufacture of pharmaceuticals, medicinal chemical and 100% botanical products 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Product/Service* NIC Code % of total Turnover contributed 1. Oral Solids 21002 57% 2. Injectables 21002 30% 3. Liquids 21002 5% *On consolidated basis III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 9 · Registered & Corporate Office-1 39 · Regional Offices- 4 · C&F locations-22 · Warehouses- 3 International - - - Annual Report 2025-26 135 Emcure Pharmaceuticals Limited 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) PAN India International (No. of Countries) 80+ b. What is the contribution of exports as a percentage of the total turnover of the entity? The contribution of exports to the total turnover of the Company during FY 2025-26 was 50.26%. c. A brief on types of customers: The Company sells its products to patients and end consumers through distributors and retailers, supplies to institutional buyers such as government bodies, and exports to international markets through its subsidiaries and other distributors. I. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): Sl. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 6,548 5,977 91% 571 9% 2. Other than Permanent (E) 119 101 85% 18 15% 3. Total employees (D + E) 6,667 6,078 91% 589 9% WORKERS 4. Permanent (F) 366 359 98% [Showing first 8,000 characters — download PDF for full document]